PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-65.79%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
143.99%
Other expenses growth 1.25-1.5x CRVO's 100.00%. Martin Whitman would scrutinize cost items.
-60.41%
Operating expenses reduction while CRVO shows 251.41% growth. Joel Greenblatt would examine advantage.
-60.41%
Total costs reduction while CRVO shows 15.98% growth. Joel Greenblatt would examine advantage.
2.95%
Interest expense change of 2.95% while CRVO maintains costs. Bruce Berkowitz would investigate control.
-100.00%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-109.95%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
62.96%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-184.33%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
47.99%
Pre-tax income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
387.82%
Tax expense change of 387.82% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
53.00%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
52.84%
EPS growth while CRVO declines. John Neff would investigate advantages.
52.84%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.